open access

Vol 23, No 3 (2018)
Original research articles
Published online: 2018-05-01
Submitted: 2017-07-18
Get Citation

CyberKnife Stereotactic Radiosurgery in brain metastases: A report from Latin America with literature review

Cuauhtémoc de la Peña, Jorge H. Guajardo, María F. Gonzalez, César González, Benjamín Cruz
DOI: 10.1016/j.rpor.2018.02.005
·
Rep Pract Oncol Radiother 2018;23(3):161-167.

open access

Vol 23, No 3 (2018)
Original research articles
Published online: 2018-05-01
Submitted: 2017-07-18

Abstract

Background and aim

Stereotactic radiosurgery is increasingly being employed for the treatment of brain metastases, both as an adjuvant to surgical resection, and also as a primary treatment modality. The aim of this study is to evaluate overall survival and local control in patients with brain metastases treated with CyberKnife Stereotactic Radiosurgery (CKRS), due to the lack of evidence reported in Latin America.

Materials and methods

We performed a retrospective chart review from October 2011 to January 2017 of 49 patients with 152 brain metastases. Clinical and prognostic factors were further analyzed by independent analysis. Kaplan–Meier curves were constructed for overall survival and local control. The median follow-up period was 12 months (range, 1–37 months).

Results

The median age was 61 years (range, 27–85 years) and Karnofsky performance status >70 in 96% of the patients. The median overall survival rate was 15.5 months (95% confidence interval [CI], 10.23–24.3 months). Overall 3-month, 6-month and 1-year local control rates were 98% (95% CI, 85–99%), 96% (95% CI, 82–99%), and 90% (94% IC, 76–96%), respectively. Local failure (LF) was observed in 6 patients (18 lesions). No late complications, such as radiation necrosis, were observed during the follow-up period.

Conclusions

CKRS achieves excellent overall survival and local control rates with low toxicity in patients with brain metastases.

Abstract

Background and aim

Stereotactic radiosurgery is increasingly being employed for the treatment of brain metastases, both as an adjuvant to surgical resection, and also as a primary treatment modality. The aim of this study is to evaluate overall survival and local control in patients with brain metastases treated with CyberKnife Stereotactic Radiosurgery (CKRS), due to the lack of evidence reported in Latin America.

Materials and methods

We performed a retrospective chart review from October 2011 to January 2017 of 49 patients with 152 brain metastases. Clinical and prognostic factors were further analyzed by independent analysis. Kaplan–Meier curves were constructed for overall survival and local control. The median follow-up period was 12 months (range, 1–37 months).

Results

The median age was 61 years (range, 27–85 years) and Karnofsky performance status >70 in 96% of the patients. The median overall survival rate was 15.5 months (95% confidence interval [CI], 10.23–24.3 months). Overall 3-month, 6-month and 1-year local control rates were 98% (95% CI, 85–99%), 96% (95% CI, 82–99%), and 90% (94% IC, 76–96%), respectively. Local failure (LF) was observed in 6 patients (18 lesions). No late complications, such as radiation necrosis, were observed during the follow-up period.

Conclusions

CKRS achieves excellent overall survival and local control rates with low toxicity in patients with brain metastases.

Get Citation

Keywords

Brain metastases; Radiosurgery; CyberKnife Stereotactic Radiosurgery

About this article
Title

CyberKnife Stereotactic Radiosurgery in brain metastases: A report from Latin America with literature review

Journal

Reports of Practical Oncology and Radiotherapy

Issue

Vol 23, No 3 (2018)

Pages

161-167

Published online

2018-05-01

DOI

10.1016/j.rpor.2018.02.005

Bibliographic record

Rep Pract Oncol Radiother 2018;23(3):161-167.

Keywords

Brain metastases
Radiosurgery
CyberKnife Stereotactic Radiosurgery

Authors

Cuauhtémoc de la Peña
Jorge H. Guajardo
María F. Gonzalez
César González
Benjamín Cruz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl